You appear to be using an older version of Internet Explorer. We suggest you upgrade your browser for the best viewing experience. Upgrade to a Modern Browser
The CJEU issued on 9 July 2020 its judgment in the Santen C-673/18 case. The judgment, which is reviewed in more detail in our briefing (here), overturns the earlier Neurim decision and concludes that SPCs are not available for new therapeutic uses of old active ingredients.
If you have any concerns or queries about the impact of this decision please speak to your usual J A Kemp contact.